Cystic Fibrosis Market Size, Analysis, Share & Forecast 2031

Report Description

The global cystic fibrosis market size was valued at USD 5.16 billion in 2021 and is estimated to reach USD 31.91 billion by 2030, expanding at a CAGR of 24.6% during the forecast period, 2022–2030. The growth of the market is attributed to increasing prevalence of cystic fibrosis across the globe.

Get Free Sample Report

Cystic Fibrosis (CF) is a hereditary disease that is caused by mutation of genes. Cystic fibrosis disease is caused by mutation in the cystic fibrosis transmembrane conductance regulator gene which is located at chromosome number 7.  Cystic fibrosis transmembrane conductance regulator gene is located in chromosome number 7. Genes control protein secretion of certain liquids in the body and are responsible for the regulation of mucus, sweat, and body secretions. Mutation caused in this gene leads to absence of CFTR activity, which results in alteration of the protein structure and cause loss of chloride. In this disease, the sweat and mucous thicken by affecting various organs in the body. Patients with these conditions face problems such as gastrointestinal system disorder and they suffer with increased infection in lower and upper respiratory tract. Physical therapy aids in the treatment of cystic fibrosis, thus helping to reduce mucous formation. Kalydeco and Pulmozyme drugs are used to cure cystic fibrosis. 

The COVID-19 pandemic negatively affected the health of human beings and changes their lifestyle, due to the imposed lockdowns. The increasing prevalence of respiratory disorders is creating the risk of cystic fibrosis. Patients affected by cystic fibrosis are at high risk of being infected by the virus. Other complications related to cystic fibrosis such as lung infection, cystic fibrosis-related diabetes, and inflammation of the pancreas gained attention of key players, who are engaged in the development of drugs and for fast recovery of patients across the globe.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing demand for treatment alternatives, due to the rising prevalence of CF, is expected to drive the market.
• Rising adoption of drug therapies is projected to propel the market during the forecast period.
• High cost of surgical treatment is anticipated to hinder the market.
• Low awareness in developing nations regarding the disease is expected to hamper the market in the coming years.
• Research and development activities are projected to create lucrative opportunities for market players. 

Scope of the Report

The report on the global cystic fibrosis market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Sweat test segment to expand at a considerable CAGR

On the basis of diagnosis types, the market is segregated into sweat test, genetic test, newborn screening, sinus X-rays, lung function tests, intestinal current measurement, nasal potential difference, sputum culture, and chest x-rays. The sweat test segment is projected to expand at a considerable CAGR during the forecast period, as it is the conclusive test for cystic fibrosis. Sweat test measures the amount of chloride present in body sweat, which is higher in patients who have cystic fibrosis. This test is not painful and does not use needle. The newborn screening segment is anticipated to account for a major market share during the forecast period, owing to the increasing testing of cystic fibrosis in newborns. 

Get Free Sample Report

Bowel surgery segment to hold a significant share of the market

Based on treatment methods, the market is divided into lung transplant, bowel surgery, feeding tube, noninvasive ventilation, oxygen therapy, and liver transplant. The bowel surgery segment is expected to hold a significant share of the market in the coming years. Bowel surgery is used to remove blockages in intestine, by using laparoscope. The lung transplant segment accounts for a significant market share. The transplantation of lung is done to replace the one or both diseased lungs from a human donor with healthy lungs. The lung transplantation is reserved for patients who have tired other medications but their condition has not satisfactorily improved. 

North America is anticipated to constitute a key market share

In terms of regions, the cystic fibrosis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to increasing prevalence of diseases and rising adoption of advanced drugs for good outcomes. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to rising healthcare facilities and high awareness associated with treatment of cystic fibrosis.

Get Free Sample Report